Balance Sheet Detail

3 Months Ended

Jan. 26, 2025

Balance Sheet Detail [Abstract]

Balance Sheet Detail

Balance Sheet Detail

 

	January 26, 2025		October 27, 2024
	(In millions)
Inventories
Customer service spares	$	1,772	$	1,742
Raw materials	1,750		1,680
Work-in-process	935		879
Finished goods
Deferred cost of sales	307		217
Evaluation inventory	443		459
Manufactured on-hand inventory	294		444
Total finished goods	1,044		1,120
Total inventories	$	5,501	$	5,421

 

	January 26, 2025		October 27, 2024
	(In millions)
Other Current Assets
Prepaid income taxes and income taxes receivable	$	54	$	120
Prepaid expenses and other	928		974
	$	982	$	1,094

	Useful Life	January 26, 2025		October 27, 2024
	(In years)	(In millions)
Property, Plant and Equipment, Net
Land and improvements		$	493	$	492
Buildings and improvements	3-30	2,406		2,359
Demonstration and manufacturing equipment	5-8	2,632		2,578
Furniture, fixtures and other equipment	3-5	796		782
Construction in progress		1,083		898
Gross property, plant and equipment		7,410		7,109
Accumulated depreciation		(3,847)		(3,770)
		$	3,563	$	3,339

	January 26, 2025		October 27, 2024
	(In millions)
Deferred Income Taxes and Other Assets
Non-current deferred income taxes	$	1,719	$	2,393
Operating lease right-of-use assets	359		375
Income tax receivables and other assets	312		314
	$	2,390	$	3,082

	January 26, 2025		October 27, 2024
	(In millions)
Accounts Payable and Accrued Expenses
Accounts payable	$	1,737	$	1,570
Compensation and employee benefits	636		1,188
Warranty	362		364
Dividends payable	325		327
Income taxes payable	635		535
Operating lease liabilities, current	81		87
Other	709		749
	$	4,485	$	4,820

 

	January 26, 2025		October 27, 2024
	(In millions)
Other Liabilities
Defined and postretirement benefit plans	$	141	$	142
Operating lease liabilities, non-current	247		259
Other	444		409
	$	832	$	810

Government Assistance

Capital expenditure related incentives reduced gross property, plant and equipment, net by $566 million as of January 26, 2025. Contra-depreciation expense was not material during the three months ended January 26, 2025. Operating incentives recognized as a reduction to research, development and engineering expense were $11 million in the three months ended January 26, 2025. Capital expenditure related incentives reduced our income taxes payable by $257 million as of January 26, 2025, of which $248 million is in accounts payable and accrued expenses and $9 million is deferred income taxes and other assets, in our Consolidated Condensed Balance Sheets.